Chemotherapy is the usual treatment for patients with a metastatic germ cell tumour (ovarian or testicular), usually given in three weekly cycles.
However, the introduction of a drug called G-CSF, which strengthens the immune system, stimulates the production of extra white blood cells, and potentially reduces the risk of serious infections, creating the possibility that people could have chemotherapy more frequently.
The trial will test drug combinations and frequency of treatment, and monitor side effects and quality of life.
Alison Birtle, Consultant Oncologist at the Cancer Centre at Lancashire Teaching Hospitals said: “The outcomes from testicular cancer treatment are already very good but with new studies we can potentially reduce treatment times and toxicity. We are delighted to be able to recruit the first UK patient into this trial.”
Claire Searle, Lead Research Nurse at Lancashire Teaching Hospitals said: “These testicular cancer patients have to be treated fairly quickly and a lot of screening work takes place to make sure they are eligible to enter into the trial. Once this is done, the data is entered and the patient is then randomised. This involves a team and lots of different departments all working together to make this happen for the patient. It’s great to have successfully recruited our first patient into this trial which is a hugely exciting development.”
Karen Partington, Chief Executive of Lancashire Teaching Hospitals said, “As the cancer centre for Lancashire and South Cumbria, as well as a leading research centre, it’s really important that we’re involved in such pioneering trials and programmes. This will enable us to bring emerging treatment and approaches to local patients now, as well as break new ground in healthcare that will benefit future generations.”